COCP (Cocrystal Pharma) Moat Score: 2/10 (As of Jun. 27, 2026)


COCP Cocrystal Pharma Inc COCP
25 GF Score
Price $1.04
! 3 Warning Signs
View Full Analysis

What is Cocrystal Pharma Moat Score?

Cocrystal Pharma COCP +0.99% 25 Moat Score is 2 as of Jun. 27, 2026. GuruFocus rates COCP with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 1,404 Biotechnology companies, Cocrystal Pharma ranks better than 58.12% on this metric.

Cocrystal Pharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Cocrystal Pharma has No Moat: Cocrystal Pharma Inc lacks significant market leadership or customer loyalty. The company operates in a highly competitive biotech sector with minimal switching costs and limited intellectual property that provides a durable advantage. Its cost structure and distribution network do not offer significant advantages over competitors.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cocrystal Pharma might have No Moat - Very weak/transient advantages.

Cocrystal Pharma  (NAS:COCP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cocrystal Pharma Moat Score Related Terms

COCP vs OSRH, CVKD, LEXX: Moat Score Comparison

For the Biotechnology subindustry, Cocrystal Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Moat Score falls into.


COCP
25GF Score
Cocrystal Pharma Inc COCP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Cocrystal Pharma (COCP) has a Moat Score of 2 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cocrystal Pharma ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Cocrystal Pharma's Moat Score too high?
Cocrystal Pharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Cocrystal Pharma's value of 2 is 0% at this industry median. Based on the distribution chart, Cocrystal Pharma ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cocrystal Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's Moat Score compare to OSRH and CVKD?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #588 out of 1404 companies for Moat Score. This puts Cocrystal Pharma in the upper half of its industry. The industry median Moat Score is 2.00. Cocrystal Pharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cocrystal Pharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (COCP) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Cocrystal Pharma's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cocrystal Pharma (COCP), the current Moat Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cocrystal Pharma Business Description

Other Exchanges 8CC:Germany
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score

Get the complete analysis for COCP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.04
Price